Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study-Reference-Cited by-同舟云学术

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study

Published:2022-01-09 Issue:2 Volume:62 Page:220-231
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Zhu Peijuan¹,Willmann Stefan²,Zhou Wangda³,Yang Haitao¹,Michelson Alan D.⁴,McCrindle Brian W.⁵,Li Jennifer S.⁶,Harris Kevin C.⁷,Pina Liza Miriam¹,Weber Traci¹,Nessel Kimberly¹,Lesko Lawrence J.⁸,Kubitza Dagmar²,Zannikos Peter¹

Affiliation:

1. Janssen Research & Development LLC Raritan New Jersey USA

2. Bayer AG, Pharmaceuticals Research and Development Wuppertal Germany

3. Janssen Research & Development LLC, Spring House Pennsylvania USA

4. Boston Children's Hospital Harvard Medical School Boston Massachusetts USA

5. The Hospital for Sick Children University of Toronto Toronto Ontario Canada

6. Duke University Medical Center Durham North Carolina USA

7. Children's Heart Centre BC Children's Hospital Vancouver BC Canada

8. University of Florida College of Pharmacy Orlando Florida USA

Publisher

Wiley

Subject